ACA's effect on drug spending is still vague, report says

11/19/2013 |

The long-term impact of the Affordable Care Act on the pharmaceutical industry in terms of drug spending is still not clear, according to a report from the IMS Institute for Healthcare Informatics. However, certain trends are recognizable, such as the greater portion of the market that will be taken by generics and biosimilars as well as drugmakers' focus moving from treatments that can provide incremental improvements to those that exhibit greater improvements. The report also projects higher spending on drugs next year as fewer patents expire and health care coverage increases.

View Full Article in:

Published in Briefs: